Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 236 participants.
Also called NCT04217421
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 236 participants
- Sponsor
- Registry
-
NCT04217421 -
2017-004596-31
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Netherlands
- Registry status
- Recruiting
Technical summary
Registry record NCT04217421. Randomized; quadruple masking; primary purpose treatment. Start 2020-02-14 (actual); primary completion 2026-10-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass
- Acronym
- CRUCIAL
- Condition
- Congenital Heart Disease in Children
- Condition
- Neuroprotection
- Intervention (Drug)
- Allopurinol
- Intervention (Drug)
- Mannitol
- Lead sponsor
- dr. M.J.N.L. Benders
- Collaborator
- ZonMw: The Netherlands Organisation for Health Research and Development
- Collaborator
- University Medical Center Groningen
- Collaborator
- Erasmus Medical Center
- Collaborator
- University Medical Center Nijmegen
- Collaborator
- ACE Pharmaceuticals BV
Record details
- Record id
cardio:ct-nct04217421- Content hash
0fee79f290b5753a036da2c045a541eef526d58a63d18bfaf9fe9d0089cd90de